Identification of LILRB4 as a regulator of M2c macrophages and a potential immunotherapeutic target in ovarian cancer
Huijuan Zhou, Qing Zhang, Bo Yin, Lingfei Han, Xiaohui Huang, Shuangdi Li · 2026
Read Identification of LILRB4 as a regulator of M2c macrophages and a potential immunotherapeutic target in ovarian cancer by Huijuan Zhou, Qing Zhang, Bo Yin, Lingfei Han, Xiaohui Huang, Shuangdi Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13454356.txt.
Description
Huijuan Zhou and five colleagues identify, in a 2026 study, a receptor called LILRB4 as a driver of ovarian cancer growth and immune escape. Ovarian cancer is the deadliest cancer of the female reproductive system. The receptor was known from blood cancers, yet its role in solid tumors was unclear.
Among its family, LILRB4 showed the highest levels in ovarian tumors, and high levels tracked with shorter survival. Turning the receptor down in lab cells slowed growth, spread, and invasion, while raising it did the opposite. Tumors rich in the receptor drew in macrophages and pushed them toward a type that suppresses immunity. The team traced this effect to a signal chain involving the chemical CCL5 and the NF-kB pathway. Lowering the receptor also made cancer cells respond better to treatment in a mouse tumor model.
Catalog record
| CREATOR | Huijuan Zhou, Qing Zhang, Bo Yin, Lingfei Han, Xiaohui Huang, Shuangdi Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |